We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Dogwood Therapeutics, Inc. is one of the oversold biotech stocks on this list.
TheFly reported on April 15 that DWTX announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for SP16, an intravenous candidate being developed for chemotherapy-induced pain and peripheral neuropathy.
The therapy is designed to act through anti-inflammatory pathways by lowering cytokines such as IL-6, IL-8, IL-1β, and TNF-alpha, while also supporting tissue repair through activation of signaling proteins involved in growth and survival. The company, together with Serpin Pharma, expects enrollment in a Phase 1b trial to begin in mid-2026, with funding fully supported by a $2.5 million National Cancer Institute grant. SP16 is intended to address significant unmet needs in CIPPN, a condition affecting a large portion of chemotherapy patients and often causing long-lasting numbness, tingling, and pain.
Separately, earlier on March 18, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) reported its fourth-quarter and full-year 2025 financial performance. Research and development spending in the fourth quarter remained unchanged at $2.3 million compared with the prior year period, while general and administrative expenses declined to $1.5 million from $5.2 million due mainly to lower one-time transaction costs linked to the 2024 business combination.
The business said that its net loss for the quarter was $3.8 million, or $0.26 per share, improving from $8.2 million a year earlier. For the full year, R&D expenses rose to $21.8 million, driven largely by SP16 licensing costs and Halneuron clinical development, while net loss widened to $35.5 million. Cash totaled $6.5 million at year-end, with additional financing extending the runway into late 2026.
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is a clinical-stage biopharmaceutical company developing non-opioid therapies for pain and neuropathic disorders, including chemotherapy-induced neuropathic pain. Its lead candidate, Halneuron, targets sodium channels to reduce pain signaling.
While we acknowledge the risk and potential of DWTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DWTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.
Disclosure: None. Follow Insider Monkey on Google News.
